DLocal (NASDAQ:DLO – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.18 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.18, FiscalAI reports. The business had revenue of $337.89 million for the quarter, compared to analyst estimates of $294.29 million. DLocal had a return on equity […]

Qfin (NASDAQ:QFIN – Get Free Report) released its quarterly earnings data on Tuesday. The company reported $1.12 EPS for the quarter, missing the consensus estimate of $1.13 by ($0.01), Zacks reports. Qfin had a return on equity of 28.73% and a net margin of 35.09%.The business had revenue of $585.10 million during the quarter, compared […]

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.17, FiscalAI reports. The business had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $0.68 million. Marker Therapeutics had a […]

Maison Solutions (NASDAQ:MSS – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.18), Zacks reports. Maison Solutions had a negative net margin of 4.89% and a negative return on equity of 46.54%. The business had revenue […]

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10), FiscalAI reports. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The firm had revenue […]

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $0.43 EPS for the quarter, beating the consensus estimate of ($0.53) by $0.96, FiscalAI reports. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue […]